TSHA 8-K 2026-11-12
Taysha Gene Therapies, Inc. (TSHA) 8-K dated 2026-11-12 — accession 0001193125-26-456974.
Taysha Gene Therapies, Inc. (TSHA) is a biotechnology company listed on US.
TSHA: Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and…
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported TSHA revenue for 2025-12-31 was $9.8M. Net income was -$109.0M. Revenue was up 17.3% from 2024-12-31 to 2025-12-31. TSHA currently screens at market cap $640.7M.
Not investment advice. The TSHA SEC hub lists recent forms. The stock page is the research view.
- Guidance
- expects that its current cash resources will support planned operating expenses and capital requirements into the
Why it matters
- expects that its current cash resources will support planned operating expenses and capital requirements into the
- During the third quarter, we continued to make strong progress across our clinical, manufacturing and commercial readiness activities as we advance toward a…